Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

BACKGROUND—: Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus (DM) are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from anti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Circulation
Egile Nagusiak: Cavender, Matthew A., Scirica, Benjamin M., Bonaca, Marc P., Angiolillo, Dominick J., Dalby, Anthony J., Dellborg, Mikael, Morais, Joao, Murphy, Sabina A., Ophuis, Ton Oude, Tendera, Michal, Braunwald, Eugene, Morrow, David A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2015
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365950/
https://ncbi.nlm.nih.gov/pubmed/25681464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.114.013774
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak